Results of a new study “support the therapeutic potential of cannabinoids in patients with OSA [obstructive sleep apnea]”.
For the study, published in the journal Sleep and epublished ahead of print by the National Institute of Health, “73 adults with moderate or severe OSA received either placebo (N=25), 2.5mg dronabinol (N=21) or 10mg dronabinol (N=27) daily, one hour before bedtime for up to 6 weeks.” Dronabinol, also called Marinol, is a synthetic THC meant to mimic the effects of natural, cannabis-based THC.
‘These findings support the therapeutic potential of cannabinoids in patients with OSA” states the study’s abstract. “In comparison to placebo, dronabinol was associated with lower AHI [Apnea–hypopnea index], improved subjective sleepiness and greater overall treatment satisfaction. Larger scale clinical trials will be necessary to clarify the best potential approach(es) to cannabinoid therapy in OSA.”